David W Buchholz

9PUBLICATIONS
74CO-AUTHORS
Innate immunityBiologically active moleculesGlycoconjugatesMedical molecular engineering of nucleic acids and proteinsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 05, 2026
SARS-CoV-2 nucleocapsid induces hyperinflammation and vascular leakage through the Toll-like receptor signaling axis in macrophages.

|Jan 06, 2026
Sulfur-containing class of broad-spectrum antivirals improves influenza virus vaccine development.

David W Buchholz, Armando Pacheco, Sreetama Pal

|Aug 27, 2025
Broad-spectrum synthetic carbohydrate receptors (SCRs) inhibit viral entry across multiple virus families.

Shahrzad Ezzatpour, Khushabu Thakur, Kenneth Erzoah Ndede

|Jan 29, 2025
Replication-incompetent VSV-based vaccine elicits protective responses against SARS-CoV-2 and influenza virus.

Richard A Adeleke, Julie Sahler, Annette Choi

|Jan 03, 2024
Adaptive immune cells are necessary for SARS-CoV-2-induced pathology.

Brian Imbiakha, Julie M Sahler, David W Buchholz

|Sep 22, 2023
Age-dependent acquisition of pathogenicity by SARS-CoV-2 Omicron BA.5.

Brian Imbiakha, Shahrzad Ezzatpour, David W Buchholz

Pageof 2

Frequent Collaborators

9 joint publications

Hector C Aguilar

7 joint publications

Mason Jager

5 joint publications

Julie Sahler

5 joint publications

Avery August